Research Funded by Us

“CCQ is the only reason I am able to continue my research into improving survival rates in head and neck cancer and breast cancer”. Dr. Fiona Simpson – CCQ research grant recipient.

You can read about our recently awarded cancer research grants below.

Accelerating Collaborative Cancer Research (ACCR) Grants


Lead Investigator: Professor Sandi Hayes

Administering Institution: Griffith University

Project Title: The ECHO trial: A randomised, controlled trial evaluating the effect of exercise during chemotherapy for ovarian cancer on survival and health resource use

Ovarian cancer has the worst survival of all gynaecological cancers, with only 45% of those diagnosed living longer than 5 years. Its treatment is associated with high levels of morbidity, declines in quality of life and unmet supportive care needs. Exercise during and post-treatment for cancer has consistently been shown to benefit function and quality of life. Yet, the vast majority of the evidence in support of exercise post-cancer stems from studies involving patients with early-stage disease and predicted ‘good’ prognosis. There is a pressing need to determine if exercise is also appropriate and beneficial in cancer cohorts with low-survival and high cancer- and treatment-related morbidity, such as is the case for women with ovarian cancer. ECHO is a clinical trial designed to determine the effects of an exercise intervention during first-line chemotherapy on survival from ovarian cancer. The study will also assess other outcomes of importance to women including function, quality of life, treatment adherence and costs. If the study shows these outcomes are better with exercise, then exercise should become part of standard care of ovarian cancer. Further, findings will provide a solid indication for the potential benefit of exercise in other cancers, including more rare cancers.

 Lead Investigator: Professor Kiarash Khosrotehrani

Administering Institution: The University of Queensland

Project Title: Advanced technological approach to predicting survival in patients diagnosed with locally invasive cutaneous melanoma

In most patients, surgical removal of a cutaneous melanoma cures the disease however in a small number of patients the melanoma may spread and ultimately lead to death. The challenge is to identify as early as possible the patients that will ultimately die, in order to give more aggressive treatment with recently developed drugs and improve their chances of survival. In this project, we propose to use established banks of melanoma tissue as well as a large group of Queensland patients with cutaneous melanoma to be followed prospectively. We will collect clinical details, genetic and gene/protein expression information in tumours and blood samples from each patient and their tumour using the latest technologies, allowing us to explore in parallel thousands of potential predictors of disease progression simultaneously. Comparing the blood and tumour sample results between those with no evidence of disease and those with a tumour relapse will help establish new pathology tests to predict an individual’s risk of tumour progression. This prospective longitudinal Queensland study will provide for the first time the means to identify patients at risk of melanoma death, raising hope for improving their survival outcomes through earlier drug therapy.

To read more about these grants click here.


The following Accelerating Collaborative Cancer Research Grants have been awarded in honour of Don and Ray Paech and their philanthropic contribution to Cancer Council Queensland.

Lead Investigator: Professor Penelope Webb

Administering Institution: QIMR Berghofer Medical Research Institute

Project Title: PROMISE: Patient-Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience

In Queensland there were more than 280,000 cancer survivors in 2015; nationally the total is expected to reach 1.4 million by 2020. It is thus important we care for those affected in the most cost-effective way. Two recent trials found cancer patients who completed regular on-line questionnaires (electronic patient-reported-outcome-measures, e-PROMs) to tell their healthcare team how they were feeling, had better quality of life and significantly better survival than those receiving usual care. However, other studies have reported more modest benefits. As these systems are being introduced into clinical practice, it is important they are tested to ensure they are both effective and cost-effective in the Australian setting. We propose a randomised trial to test the effectiveness and cost-effectiveness of the use of ePROM tools in routine cancer care to improve patient outcomes. If the tools are effective, this would lead to improved quality of life for cancer patients and lower mortality rates. They would particularly benefit those in rural/remote areas who have to travel to major centres for follow-up. It will also support adaptation of the tools, co-designed with specific cultural populations to ensure relevance, further optimise access and ensure equality for all Queenslanders with cancer.

Lead Investigator: Professor Mark Smyth

Administering Institution: QIMR Berghofer Medical Research Institute

Project Title: LUCKI STARS: Lung cancer knowledge in immunogenomics to stratify therapeutic resistance and sensitivity

LUCKI STARS (Lung cancer knowledge in immunogenomics to stratify therapeutic resistance and sensitivity) is a new 11-member multi-disciplinary research network dedicated to developing diagnostic tools and therapeutic interventions to improve our understanding of lung cancer patient response or resistance to immunotherapy. Immunotherapy describes a collection of biological agents that boost the patient’s immune system to fight disease. These therapies work very well in some lung cancer patients, but not others. The team wants to know why this is and how to make this strategy effective for every patient. The team comprises cross disciplinary expertise including clinical care of lung cancer, and research experts in genomics, immunology and detection/prognostic biomarkers. Lung cancer is a major killer and key unmet clinical needs are to: 1) understand lung cancer patient response and resistance to current immunotherapy; 2) develop biomarkers of lung cancer response and resistance; and 3) treat lung cancer earlier with new combination immunotherapies. The team will interrogate the best available human lung cancer samples from clinical trial patients pre- and post-treatment. They will be using a variety of cutting-edge, integrated methodological approaches to evaluate the cancer cells and immune cells to improve patients’ response to therapies.

Current Cancer Research Project Grants

2019 – 2020

Dr Bryan Day, QIMR Berghofer Medical Research Institute

Dystroglycan Complex Targeting: A Novel Approach to Eliminate Tumour-Initiating Cells in Adult Brain Cancer

Glioblastomas (GBMs) are the most common and aggressive brain cancers. It is now becoming understood that solid tumours are made of many types of cancerous cells including cancer stem cells. It is thought that these cells are responsible for tumour initiation and recurrence. We have identified a cell receptor termed dystroglycan, which keeps brain cancer cells in an aggressive state. We are now investigating approaches to target this receptor to prolong brain cancer patient survival.

Professor Riccardo Dolcetti, The University of Queensland

Strategies to overcome immune-resistance to cancer vaccines

This project seeks to take advantage from our novel, versatile and effective cancer vaccine platform to explore strategies able to overcome two major mechanisms of immune resistance to cancer immunotherapy: the defective ability of some tumours to present antigens to the immune system and the immune suppression induced by excessive inflammation. The full exploitation of the therapeutic potential of our novel cancer vaccine will enhance the applicability and efficacy of cancer immunotherapy.

Associate Professor Juliet French, QIMR Berghofer Medical Research Institute

Combining genetics and genomics to identify multi-cancer risk genes.

Hormone-related cancers represent a major health and economic burden. Collectively, breast, ovarian, endometrial and prostate cancers accounted for more than 28% of all cancers diagnosed in Australia last year. This project will identify the key genes responsible for risk of multiple cancers. These multi-cancer genes may represent novel drug targets that could be used to prevent or treat multiple cancer types.

Professor Nikolas Haass, The University of Queensland

Induction of endoplasmic reticulum stress to potentiate immunogenic cell death to improve melanoma therapy

Utilising unique microscopy techniques, we have demonstrated that bortezomib causes cell stress and subsequent cell death of melanoma cells.

Moreover, our preliminary data demonstrate that treatment with bortezomib results in the upregulation of proteins that mark the melanoma cells for identification by the immune system. We hypothesise that bortezomib can be used as an immunogenic cell death inducer to enhance anti-tumour responses in melanoma.

Dr Brett Hollier, Queensland University of Technology

Targeting the adaptive response to androgen-deprivation as an adjuvant therapy for advanced prostate cancer

Prostate cancer accounts for over 3,000 deaths annually in Australia, which is due to the ability of cancer cells to adapt and survive current treatments. We have identified a protein, Neuropilin-1 (NRP1), which may be involved in this adaptive response to therapy and allow cancer cells to progress to a treatment-resistant state. This study will define the role for NRP1 in tumour progression and test two agents that block NRP1 function as potential novel therapies for advanced prostate cancer.

Professor Kum Kum Khanna, QIMR Berghofer Medical Research Institute

To investigate the mechanistic and functional roles of MLK4 in mediating radio-resistance of breast cancer stem cells

Numbers of studies have suggested the importance of targeting cancer stem cells (CSCs) in patients who suffer a cancer relapse. Our current data suggest that MLK4 is a promising molecular target in mediating changes of CSC populations in response to radiotherapies using ionising radiation. We thus propose to investigate molecular mechanism attributing to the incomplete elimination of CSCs during radiotherapy, establishing a new potential target to overcome cancer relapse.

Professor Gregory Monteith, The University of Queensland

Exploiting remodelling of calcium signalling to specifically target triple negative breast cancer via promotion of apoptosis

Triple negative breast cancers are a type of breast cancer that is still not treated effectively. Women with this disease are more likely to have their breast cancer spread to the lung and the brain. The work in this grant builds on the identification of drug targets that are at high levels in this type of breast cancer. When these drug targets are inhibited, triple negative breast cancer cells are more likely to undergo cell death with exposure to cancer therapies.

Associate Professor Helmut Schaider, The University of Queensland

O-linked-N-acetylglucosamine transferase and ten-eleven translocation 1 facilitate therapy induced cellular reprogramming leading to acquired drug resistance in cancer

Drug resistance is an ever occurring problem for a successful treatment in cancer patients. One of the mechanisms assumed leading to permanent resistance is an adaptive generic process based on a chronic stress response. We have identified two factors involved in this stress response. One can be targeted by small compounds or peptides which will be developed and tested in preclinical models. Inhibition of these factors will allow for improved survival and prolonged remission in cancer patients.

Professor Mark Smyth, QIMR Berghofer Medical Research Institute

Nectin-like molecules in cancer

Immunotherapy is emerging as an alternative to standard anti-cancer therapies, but many patients still do not benefit from these immunotherapies. We have early data to show that a stress-induced molecule, CD155, expressed on immune and tumour cells, promotes tumour growth and spread. We hypothesise CD112 does similar and may act in concert with CD155, to hinder contemporary immunotherapy. We wish to further study these pathways in animal models and responder and non-responder patient samples.

Associate Professor Vicki Whitehall, QIMR Berghofer Medical Research Institute

High Risk Sessile Serrated Adenomas of the Colorectum

Bowel cancer is very common and will be diagnosed in 1/12 Australians living to age 85. Fortunately we can prevent bowel cancer from developing by removing the small growths, called polyps, that precede development of cancer. This application proposes to look at a specific type of bowel polyp called a sessile serrated adenoma, which is difficult to detect and can progress rapidly to cancer. We will develop markers to predict risk of these polyps to inform surveillance guidelines.